Skip to main content

Wedbush Sticks to Their Buy Rating for IMAX (IMAX)

Tipranks - Tipranks - Tue Feb 24, 7:16AM CST

In a report released today, Martin Fan from Wedbush reiterated a Buy rating on IMAX, with a price target of $46.00.

Claim 50% Off TipRanks Premium

Fan covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, Oruka Therapeutics, and Zenas BioPharma, Inc.. According to TipRanks, Fan has an average return of 30.1% and a 60.00% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IMAX with a $44.00 average price target.

See the top stocks recommended by analysts >>

Based on IMAX’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $106.15 million and a net profit of $20.66 million. In comparison, last year the company earned a revenue of $91.45 million and had a net profit of $13.9 million

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IMAX in relation to earlier this year. Most recently, in November 2025, Natasha Fernandes, the CFO & EVP of IMAX sold 2,652.00 shares for a total of $95,843.28.

Read More on IMAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).